We are developing diagnostic assays to identify patients who are most likely to respond to targeted cancer therapies. Our first assay for RasGRP1, has been clinically validated as a predictive and prognostic marker for response to anti-EGFR therapy in metastatic colorectal cancer.
We are currently exploring other indications where inhibition of the EGFR pathway is a central therapeutic modality, and uncovering more about the role of RasGRP1 in regulation of this key signaling pathway.
Company Details
- Founded
- 2016
- Address
- San Francisco, Ca 94158, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://sealbiosciences.com
- HQ
- San Francisco, ca
Seal Biosciences Questions
Seal Biosciences's website is https://sealbiosciences.com
Seal Biosciences's LinkedIn profile is https://www.linkedin.com/company/seal-biosciences
Seal Biosciences's industry is
Biotechnology Research
Seal Biosciences's top competitors are
St-Diagnostic,
Mitophilix,
Metimedi Co., Ltd.,
St Innovative Diagnostics Ltd.,
Rhemastem Srls,
Chess Therapeutics, Llc,
Oncodata,
Theravax,
Synchrony,
Epigenetic Data Sciences.
Seal Biosciences's categories are Biotechnology Research
Seal Biosciences's founding year is 2016
